Business, energy, technology, markets and global industry news from Business News Today

SV-102

PharmaDeviceNews SV-102
Representative image of metastatic prostate cancer research as Syncromune’s investigational SYNC-T immunotherapy demonstrates 80% two-year survival and durable complete responses in an early Phase 1 clinical trial.
Pharma & Biotech

SYNC-T prostate cancer treatment shows encouraging long-term survival as LEGION-100 trial expands

Syncromune's SYNC-T therapy shows 80% two-year survival in a Phase 1 metastatic prostate cancer trial. Explore results and Phase 2a plans.

Read More
Pharma & Biotech

What Syncromune Inc.’s SYNC-T data reveals about the future of combination immunotherapy

Discover how Syncromune Inc.’s SYNC-T data could reshape combination immunotherapy. Find out what this means for cancer treatment innovation.

Read More